biostudies-literatureUnknown13(8)Garcia-Arroyo FEKibow Biotech, Newtown Square, PA, USAHyperuricemia is highly prevalent and especially common in subjects with metabolic, cardiovascular and renal diseases. In chronic kidney disease, hyperuricemia is extremely common, and uric acid (UA) excretion relies on gut uricolysis by gut microbiota. Current therapy for lowering serum UA includes drugs that may produce undesired secondary effects. Therefore, this pilot study was designed to evaluate the potential of two probiotic supplements to reduce systemic uric acid concentrations. Secondary objectives were to assess whether the hypouricemic effect related to a therapeutic benefit on the hyperuricemia-induced renal damage and hypertension. Analysis of fecal microbiota was also performed. Groups of 6 rats each were followed for 5 weeks and allocated in the following treatment groups:PloS onee0202901https://www.ebi.ac.uk/biostudies/studies/S-EPMC6108486biostudies-literatureProbiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage.PMC6108486Robertson CERanganathan PRanganathan NFrank DNJohnson RJTapia EIrvin AMunoz-Jimenez IGonzaga GIr DSilverio OGarcia-Arroyo FEBlas-Marron MGSoto VSanchez-Lozada LGVyas UfalseProbiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage.Hyperuricemia is highly prevalent and especially common in subjects with metabolic, cardiovascular and renal diseases. In chronic kidney disease, hyperuricemia is extremely common, and uric acid (UA) excretion relies on gut uricolysis by gut microbiota. Current therapy for lowering serum UA includes drugs that may produce undesired secondary effects. Therefore, this pilot study was designed to evaluate the potential of two probiotic supplements to reduce systemic uric acid concentrations. Secondary objectives were to assess whether the hypouricemic effect related to a therapeutic benefit on the hyperuricemia-induced renal damage and hypertension. Analysis of fecal microbiota was also performed. Groups of 6 rats each were followed for 5 weeks and allocated in the following treatment groups:2018-01-01T00:00:00Z20182026-04-07T21:47:17.391Z2019-03-26T23:56:03ZS-EPMC61084863014217310.1371/journal.pone.0202901